Rockwell Medical Q2 2025 revenue drops 38% to $16.1M, net loss of $1.5M

ROCKWELL MEDICAL, INC.

2025-Q2 EPS reported -$0.09 revenue$34,985,000

Net sales $16.1M, down 38% YoY, driven by loss of largest customer; gross margin 16% in line with guidance.
Net loss $1.5M vs net income $0.3M in Q2 2024; Adjusted EBITDA -$0.2M vs $1.4M year ago.
Cash & investments increased to $18.4M, supported by $1.8M operating cash flow.
Reaffirmed 2025 guidance: net sales $65-70M, gross margin 16-18%, Adj EBITDA -$0.5M to $0.5M.
Secured multi-year supply agreements with Innovative Renal Care (3-yr) and other providers; >80% customers under long-term contracts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.